PEJIVITAY Trademark

Trademark Overview


On Wednesday, November 18, 2020, a trademark application was filed for PEJIVITAY with the United States Patent and Trademark Office. The USPTO has given the PEJIVITAY trademark a serial number of 90327858. The federal status of this trademark filing is ABANDONED - EXPRESS AFTER PUB as of Friday, May 31, 2024. This trademark is owned by Eli Lilly and Company. The PEJIVITAY trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of alopecia, Alzheimer's disease, atopic dermatitis, autoimmune diseases and disorders, blood diseases and disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cluster headaches, Coronavirus disease, Crohn's disease, dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, fibromyalgia, gastrointestinal diseases and disorders, headaches, heart failure, inflammation and inflammatory diseases and disorders, inflammatory bowel disease, kidney diseases and disorders, liver diseases and disorders, lupus, mental disorders, metabolic diseases and disorders, migraines, neurodegenerative diseases and disorders, neurological disorders, obesity, osteoarthritis, pain, Parkinson's disease, Psoriasis, Psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, vascular diseases
pejivitay

General Information


Serial Number90327858
Word MarkPEJIVITAY
Filing DateWednesday, November 18, 2020
Status605 - ABANDONED - EXPRESS AFTER PUB
Status DateFriday, May 31, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, June 8, 2021

Trademark Statements


Goods and ServicesPharmaceutical preparations, namely, pharmaceutical preparations for the treatment of alopecia, Alzheimer's disease, atopic dermatitis, autoimmune diseases and disorders, blood diseases and disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cluster headaches, Coronavirus disease, Crohn's disease, dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, fibromyalgia, gastrointestinal diseases and disorders, headaches, heart failure, inflammation and inflammatory diseases and disorders, inflammatory bowel disease, kidney diseases and disorders, liver diseases and disorders, lupus, mental disorders, metabolic diseases and disorders, migraines, neurodegenerative diseases and disorders, neurological disorders, obesity, osteoarthritis, pain, Parkinson's disease, Psoriasis, Psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, vascular diseases

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code8 - Abandoned
Class Status DateFriday, May 31, 2024
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameEli Lilly and Company
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressIndianapolis, IN 46285

Party NameEli Lilly and Company
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressIndianapolis, IN 46285

Trademark Events


Event DateEvent Description
Saturday, November 21, 2020NEW APPLICATION ENTERED
Friday, January 22, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, April 29, 2021ASSIGNED TO EXAMINER
Monday, May 3, 2021APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, June 8, 2021PUBLISHED FOR OPPOSITION
Wednesday, May 19, 2021NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, June 8, 2021OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, August 3, 2021NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Thursday, January 20, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, January 10, 2022SOU TEAS EXTENSION RECEIVED
Monday, January 10, 2022SOU EXTENSION 1 FILED
Wednesday, January 19, 2022SOU EXTENSION 1 GRANTED
Wednesday, January 19, 2022CASE ASSIGNED TO INTENT TO USE PARALEGAL
Tuesday, July 19, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, July 13, 2022SOU TEAS EXTENSION RECEIVED
Wednesday, July 13, 2022SOU EXTENSION 2 FILED
Saturday, July 16, 2022SOU EXTENSION 2 GRANTED
Thursday, January 12, 2023SOU TEAS EXTENSION RECEIVED
Wednesday, January 10, 2024SOU EXTENSION 5 FILED
Thursday, January 12, 2023SOU EXTENSION 3 FILED
Thursday, January 12, 2023SOU EXTENSION 3 GRANTED
Saturday, January 14, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, July 11, 2023SOU TEAS EXTENSION RECEIVED
Tuesday, July 11, 2023SOU EXTENSION 4 FILED
Tuesday, July 11, 2023SOU EXTENSION 4 GRANTED
Thursday, July 13, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, January 10, 2024SOU TEAS EXTENSION RECEIVED
Thursday, January 11, 2024SOU EXTENSION 5 GRANTED
Thursday, May 30, 2024TEAS EXPRESS ABANDONMENT RECEIVED
Friday, May 31, 2024ABANDONMENT NOTICE E-MAILED - AFTER PUBLICATION
Friday, May 31, 2024ABANDONMENT - AFTER PUBLICATION
Friday, January 12, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED